Recent studies have demonstrated its value in diverse clinical contexts, underscoring its potential to generate reliable evidence when RCTs are infeasible. In this study, we therefore applied a sequential TTE using electronic health records from the 7.5 million population in Hong Kong to investigate whether SGLT2 inhibitors may improve prognosis in patients with prostate cancer receiving hormone therapy, including ADT and NHAs. Here, SLC5A2 is linked to prostate carcinoma.